AR DNA Binding Protein 34 kDa (TDP-43) pathology has been associated with familial and sporadic forms of amyotrophic lateral sclerosis ... and denervated motor end plates (AChRs) in the ...

(MENAFN- EIN Presswire) Numerous companies, such as Kyowa Kirin, GSK, AstraZeneca, aTyr Pharma, and others, are actively developing treatments in the Systemic Sclerosis market. LAS VEGAS ...

A new electrically active transplantable material that can help to regrow cells in the brain and spinal cord could redefine ...

Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks BioNxt Solutions has made significant progress in developing BNT23001, a new treatment for Multiple Sclerosis ...

Pick the best stocks and maximize your portfolio: BioNxt Solutions has made significant progress in developing BNT23001, a new treatment for Multiple Sclerosis, achieving key milestones in 2024.

Recent research led by UTHealth Houston scientists has uncovered two genes associated with variants linked to epilepsy, which ...

Tuberous sclerosis (TS), or tuberous sclerosis complex ... but most people can expect to have a normal lifespan. Treatments are targeted at individual symptoms, and careful monitoring by your ...

- Virtual reality might improve balance and postural control, upper limb function, and participation and quality of life, but the overall quality of the evidence is limited. - Since these results are ...

Having presented new data at last year’s European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Annual Meeting – where the safety and efficacy of Novartis’ Kesimpta ...